[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-dysfunction-associated-steatotic-liver-disease-masld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-dysfunction-associated-steatotic-liver-disease-masld":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,82,109,137,160,186,207,233],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100580887","stimulating-fat-tissue-storage-with-niacin-to-reduce-fat-accumulation-in-the-liver-100580887",false,"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).","AGL13","Inclusion Criteria:\n\n* aged 20 to 80 years;\n* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria;\n\nExclusion Criteria:\n\n1\\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \\> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \\> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], and platelet count), 1.3 serum ALT \\> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.\n\n5\\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.\n\n8\\) Being allergic to eggs 9) Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day.\n\n10\\) Women who are pregnant or breastfeeding.","ALL","20 Years","80 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation\u002F fibrosis. MASLD results from fat being disproportionately deposited in the liver.\n\nThe goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment.\n\nThe main questions it aims to answer are:\n\n* Does Niacin lower the fat deposition in the liver?\n* Does Niacin raise White Adipose Tissue storage of dietary fatty acids?\n\nResearchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response.\n\nDuration of study per participant: Up to 28 weeks",[28,29,30],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[32,33,34,35],"Fatty liver","Niacin","vitamin B3","nicotinic acid","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-22",{"date":44,"type":22},"2030-07",{"name":46,"class":47},"Université de Sherbrooke","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100633532","phase-2-a-phase-2a-study-of-aln-pnp-with-and-without-a-glp1r-agonist-in-adult-patients-with-homozygous-pnpla3-related-masld-100633532","NCT07527910","A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD","A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Key Inclusion Criteria:\n\nPart A and Part B:\n\n1. Homozygous for the PNPLA3 p.I148M genotype\n2. Liver fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥15% at visit 3\n3. Has a Body Mass Index (BMI) ≥30 to \\\u003C45 kg\u002Fm\\^2 at visit 2\n\nPart A: To be eligible for randomization on study day 1:\n\n1. Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤3 × Upper Limit of Normal (ULN) as described in the protocol\n2. On a stable dose of tirzepatide at randomization (≥5 mg weekly)\n\nKey Exclusion Criteria:\n\n1. Evidence or diagnosis of portal hypertension or cirrhosis from any cause, including cirrhosis due to MASH, as determined by the investigator, based on medical history, clinical assessment, imaging, and\u002For liver biopsy\n2. Known chronic liver disease other than MASLD, as determined by the investigator, as defined in the protocol\n3. Contraindications to MRI examinations, including but not limited to persons with MRI-incompatible cardiac pacemaker and implants made of metal, severe claustrophobia, size restrictions\n4. Any contraindication listed in the Zepbound United States Prescribing Information (USPI), as defined in the protocol\n\nNOTE: Other protocol-defined inclusion\u002Fexclusion criteria apply.","18 Years","75 Years",{"count":59,"type":22},204,[61],"PHASE2","This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein.\n\nThe goal of this study is to understand the effect of ALN-PNP with or without tirzepatide on reducing liver fat.\n\nThe study is looking at:\n\n* How well ALN-PNP with and without tirzepatide works\n* What side effects ALN-PNP might cause\n* How much ALN-PNP is in the blood at different times\n* How the body and the liver change after having ALN-PNP, which can help researchers understand why ALN-PNP works better in some people than others",[64],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",[66,67,68,69,70],"Homozygous PNPLA3-Related MASLD","Fatty Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Nonalcoholic Steatohepatitis (NASH)","2026-06-23",{"date":73,"type":40},"2026-06-26",{"date":75,"type":40},"2026-05-22",{"date":77,"type":22},"2030-03-15",{"name":79,"class":80},"Regeneron Pharmaceuticals","INDUSTRY",5,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":87,"conditions":93,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100635513","phase-1-evaluating-the-pharmacokinetics-and-safety-of-miricorilant-100635513","NCT07553663","Evaluating the Pharmacokinetics and Safety of Miricorilant","A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Inclusion Criteria:\n\n* Evidence of presumed MASH with either FibroScan liver stiffness measurement ≥ 8 kPa and controlled attenuation parameter (CAP) ≥ 280 dB\u002Fm OR historical biopsy within 12 months of screening that meets the following criteria:\n\n  1. Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 3 with at least ≥ 1 point in any two subcomponents of steatosis, inflammation, and ballooning, and a Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) fibrosis score of F1 OR\n  2. NAS ≥ 2 with at least ≥ 1 point in any two subcomponents of steatosis, inflammation, and ballooning, and a NASH CRN fibrosis score of F2 or 3.\n* Aspartate aminotransferase (AST) \\> 17 U\u002FL for women and AST \\> 20 U\u002FL for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of Screening.\n* Presence of at least 1 of the following metabolic conditions that increase the risk of MASH:\n\n  1. Diagnosis of type 2 diabetes OR\n  2. Presence of 2 or more components of metabolic syndrome:\n\n     * Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or treatment for elevated blood glucose\n     * Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension\n     * Serum triglycerides ≥ 150 mg\u002FdL (1.7 mmol\u002FL) or drug treatment for elevated triglycerides\n     * Serum high-density lipoprotein (HDL) cholesterol \\\u003C 40 mg\u002FdL (1 mmol\u002FL) in men and \\\u003C 50 mg\u002FdL (1.3 mmol\u002FL) in women or drug treatment for low HDL\n     * Overweight or obese (body mass index \\[BMI\\] ≥ 25 kg\u002Fm2 \\[BMI ≥ 23 kg\u002Fm2 in Asians\\]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm \\[35.4 in\\]; women ≥ 80 cm \\[31.5 in\\] in Asians).\n\nExclusion Criteria:\n\n* Women who are pregnant, planning to become pregnant, or are lactating.\n* Have a BMI \\\u003C 18 kg\u002Fm2 or \\> 45 kg\u002Fm2.\n* Have significant alcohol consumption of more than 20 g per day for women and 30 g per day for men within 1 year prior to screening or score of ≥8 on AUDIT questionnaire\n* Have had liver transplantation or plan to have liver transplantation during the study.\n* Have type 1 diabetes.\n* Have poorly controlled type 2 diabetes with a glycated hemoglobin (HbA1c)\n\n  * 9.5%.\n* Have any other chronic liver disease\n* History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver biopsy evaluation\n* Have hepatic decompensation\n\nOther exclusion criteria may apply",{"count":90,"type":22},15,[92],"PHASE1",[70,94,28,95],"Metabolic Dysfunction-Associated Steatohepatitis (MASH) \u002F Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis","Non-alcoholic Fatty Liver Disease (NAFLD)",[97,70,98,99],"Nonalcoholic Fatty Liver Disease (NAFLD)","Metabolic dysfunction-Associated Steatohepatitis (MASH)","Metabolic dysfunction-Associated Steatosis Liver Disease (MASLD)","2026-05-21",{"date":102,"type":40},"2026-05-26",{"date":104,"type":40},"2026-04-30",{"date":106,"type":22},"2026-10-30",{"name":108,"class":80},"Corcept Therapeutics",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},"100489061","phase-1-a-trial-to-learn-if-aln-pnp-is-safe-and-well-tolerated-in-healthy-adults-and-adult-participants-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100489061","NCT05648214","A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","A Three-Part, Phase 1\u002F2a, Randomized, Double-blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With MASLD","Key Inclusion Criteria:\n\nPart A (Healthy Adults):\n\n1. From 18 to 55 years of age\n2. For Japanese cohorts ONLY; the Japanese participant must:\n\n   1. Be Japanese, born in Japan, and have both biologic parents and 4 biologic grandparents who are ethnically Japanese and born in Japan\n   2. Have maintained a Japanese lifestyle, with no significant change since leaving Japan, including having access to Japanese food and adhering to a Japanese diet\n   3. Be living \\\u003C10 years outside of Japan\n3. Has a Body Mass Index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive, at the screening visit\n4. Is judged by the investigator to be in good health, as described in the protocol\n5. Is in good health based on laboratory safety testing obtained at the screening visit and approximately within 24 hours prior to administration of study drug\n\nPart B and Part C (Participants with MASLD):\n\n1. Part B: From 18 to 65 years of age\n2. Part C: From 18 to 75 years of age\n3. BMI from 23.0 kg\u002Fm2 to 40.0 kg\u002Fm2, inclusive, for East Asians (including but not limited to South Koreans, Chinese, Taiwanese, and Japanese) and BMI from 27.0 kg\u002Fm2 to 40.0 kg\u002Fm2, inclusive, for any other ethnicity at screening visit 1\n4. Liver fat content ≥8.5% as measured by MRI-PDFF at screening visit 3\n\nKey Exclusion Criteria:\n\nPart A:\n\n1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, neurological, or dermatologic disease, as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation\n2. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study\n3. Hospitalized for any reason within 30 days of the screening visit\n4. Using the Modification of Diet in Renal Disease equation, has a glomerular filtration rate as described in the protocol at the screening visit\n5. Has Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) or total bilirubin above the Upper Limit of Normal (ULN) range\n6. Is a current smoker or former smoker, including e-cigarettes, who stopped smoking within 3 months prior to the screening visit\n7. Has a history of alcohol or drug abuse per investigator opinion\n8. Is positive for hepatitis C antibody and if so, positive for qualitative (ie, detected or not detected) Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) test at the screening visit\n\nPart B and Part C:\n\n1. Evidence of other forms of known chronic liver disease, as defined in the protocol\n2. Has a contraindication to MRI examinations, as defined in the protocol\n3. History of Type 1 diabetes\n4. Has lost or gained more than 4.0% body weight over the 3 months prior to or during the screening period\n5. Has known Human Immunodeficiency Virus (HIV) infection, evidence of current or chronic Hepatitis B Virus (HBV) infection, or current or chronic HCV infection, as defined in the protocol\n6. Bariatric surgery within approximately 5 years (Part B) or 3 years (Part C) prior or planned during the study period\n\nNOTE: Other protocol defined inclusion \u002F exclusion criteria apply",true,{"count":118,"type":22},172,[92,61],"This study is researching an experimental drug called ALN-PNP (called \"study drug\"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug Administration (FDA) for any kind of treatment.\n\nThis study consists of 3 parts. Part A is focused on healthy participants. Parts B and C of the study are focused on participants who are known to have MASLD and a specific variant of the PNPLA3 gene.\n\nThe aim of the study is to see how safe, tolerable and effective the study drug is.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug (Parts A, B and C)\n* How much study drug (Parts A, B and C) and study drug metabolites (byproduct of the body breaking down the study drug) (Parts B and C) are in the blood at different times\n* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) (Part A, B and C)\n* Explore impact of Japanese ethnicity on safety and PK (Pharmacokinetics, or study of what the body does to the drug) of single doses of ALN-PNP over time (Part A)\n* How the study drug works to change liver fat content in MASLD (Part B and C)\n* Better understanding of the study drug and MASLD (Part B and C)",[122,64],"Healthy Volunteers",[124,125,126,127,69,98],"Liver steatosis","Fibrosis","Hepatocytes","Non-Alcoholic Steatohepatitis (NASH)","2026-04-13",{"date":130,"type":40},"2026-04-16",{"date":132,"type":40},"2022-12-27",{"date":134,"type":22},"2027-08-10",{"name":79,"class":80},6,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100631078","phase-2-same-for-prevention-of-liver-cancer-in-masld-related-cirrhosis-100631078","NCT07495995","SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis","A Single-center, Phase II Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Effect of S-adenosyl-L-methionine (SAMe) in Prevention of Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD)-Related Cirrhosis","SAMeMASLDc-02","Inclusion Criteria:\n\n1. individuals 18 years old or above.\n2. Understand the study procedures and able to provide informed consent.\n3. Clinical diagnosis of MASLD per American Association for the Study of Liver Diseases (AASLD) guideline: Patients with hepatic steatosis identified by imaging or biopsy, AND have at least one of five cardiometabolic risk factors:\n\n   (i) BMI ≥25 kg\u002Fm2 (23 kg\u002Fm2 for Asian) OR waist circumference \\>94 cm for male or \\>80 cm for female.\n\n   (ii) Fasting serum glucose ≥5.6 mmol\u002FL (100 mg\u002FdL) OR 2-hour post-load glucose levels ≥7.8 mmol\u002FL (140 mg\u002FdL) OR HbA1c ≥5.7% (39 mg\u002FdL) OR type 2 diabetes OR treatment for type 2 diabetes (iii) Blood pressure ≥130\u002F85 mmHg OR specific antihypertensive drug treatment. (iv) Plasma triglycerides ≥1.7 mmol\u002FL (150 mg\u002FdL) OR lipid lowering treatment (v) Plasma HDL-cholesterol ≤1.0 mmol\u002FL (40 mg\u002FdL) for male or ≤1.3 mmol\u002FL (50 mg\u002FdL) for female OR lipid lowering treatment.\n4. Current weekly intake of alcohol \\\u003C210 g (7.41 oz) for male or weekly intake of alcohol \\\u003C140 g (4.76 oz) for female, \\[1 oz\u002F30 mL of alcohol is present in one 12 oz\u002F360 mL beer, 4 oz\u002F120 mL glass of wine, and a 1oz\u002F30 mL measure of 40 proof (20%) alcohol\\]\n5. Diagnosis of cirrhosis confirmed via histopathology OR at least two of the following measures:\n\n   (i) Transient elastography (FibroScan® ≥ 12 kPa) (ii) Computed tomography (iii) MRI including MR elastography (stiffness ≥ 4.71 kPa) (iv) Abdominal Ultrasound\n6. Patient had imaging for HCC screening (Ultrasound or MRI or CT) within 3 months prior to screening.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of HCC prior to screening, any suspicious nodules identified prior or during screening must be followed with documentation of HCC negative confirmed prior to randomization.\n2. History of other causes of liver disease, including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders (primary biliary cholangitis, primary sclerosing cholangitis, or autoimmune hepatitis), drug-induced hepatotoxicity, Wilson's disease, iron overload, or alpha-1-antitrypsin deficiency.\n3. Most recent serum creatinine \\>1.5 mg\u002Fdl within 3 months prior to screening.\n4. Active infection with positive urine culture, blood culture, or pneumonia at screening.\n5. History of gastrointestinal bleeding within the prior 28 days\n6. History of liver transplantation.\n7. Women who are pregnant or nursing at screening.\n8. Significant systemic illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the investigator would preclude the patient from participating in the study or poses a significant risk of mortality during the study period, such as conditions that are interfering with the absorption, distribution, metabolism, or excretion of S-adenosyl-L-methionine (SAMe) such as those with gastric bypass surgery.\n9. HIV infection or patients who are immunocompromised.\n10. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening.\n11. Systemic antibiotic use or use of rifaximin for 10 days or more within the last 2 months prior to screening.\n12. Actively taking investigational or over-the-counter SAMe within 28 days prior to screening.\n13. Subjects with psychiatric illnesses such as bipolar disorders and Parkinson's disease as SAMe may interfere with the levels of anti-psychotic drugs and might interact with drugs and dietary supplements that increase levels of serotonin (a chemical produced by nerve cells), such as antidepressants, L-tryptophan, and St. John's wort.\n14. Members from the same family of study participant.",{"count":146,"type":22},94,[61],"This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. Investigators will assess whether treatment is associated with changes in liver-related clinical measures, biologic markers, and other study outcomes relevant to disease progression. The goal of this study is to generate early data to determine whether SAMe should be studied further as a potential therapeutic strategy in patients with MASLD cirrhosis.",[64],"NOT_YET_RECRUITING","2026-03-26",{"date":153,"type":40},"2026-03-31",{"date":155,"type":22},"2026-04-15",{"date":157,"type":22},"2031-12-31",{"name":159,"class":47},"Cedars-Sinai Medical Center",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":166,"maxAge":56,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100629910","the-effect-of-the-dash-diet-on-clinical-and-metabolic-parameters-in-children-with-masld-100629910","NCT07480811","The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD","Inclusion Criteria:\n\n* Eligibility criteria include being between 11 and 18 years of age,\n* Having a body mass index (BMI) ≥95th percentile,\n* Having hepatic steatosis detected by magnetic resonance imaging (MRI) and proton density fat fraction (PDFF) measurement (cutoff value ≥5%).\n\nExclusion Criteria:\n\n* Other liver diseases (such as viral hepatitis, autoimmune hepatitis, Wilson's disease),\n* Alcohol consumption,\n* History of type I or type II diabetes,\n* Use of medications that may affect fatty liver or blood lipid profile (corticosteroids, metformin, vitamin E, omega-3 fatty acids, etc.),\n* Having participated in a weight loss program or undergone bariatric surgery prior to the study,\n* Presence of chronic inflammatory disease, thyroid dysfunction (hyperthyroidism and hypothyroidism),\n* Having received antibiotic treatment and used nutritional supplements in the last 3 months prior to the study,\n* Having a psychiatric disorder that may affect adherence to the diet or the safety of exercise.","11 Years",{"count":168,"type":22},88,[25],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in childhood is becoming increasingly prevalent, paralleling the rise in obesity rates, and has become the most common chronic liver disease in the pediatric population. MASLD is associated with metabolic mechanisms such as insulin resistance, dyslipidemia, oxidative stress, and inflammation, and can progress to serious complications like steatohepatitis, fibrosis, and cirrhosis in later stages. Currently, pharmacological treatments for managing MASLD are limited, and lifestyle modifications, particularly dietary interventions, stand out as the primary approach for preventing and treating the disease. In this context, the composition of macro and micronutrients plays a critical role in the development and progression of hepatic steatosis.\n\nWithin this framework, the Dietary Approaches to Stop Hypertension (DASH) diet is a balanced eating pattern that encourages the consumption of vegetables, fruits, whole grains, legumes, low-fat dairy products, fish, poultry, and healthy fat sources, while limiting sodium, saturated fat, sugary foods, and processed meat products. Similar to the Mediterranean diet, the DASH diet is a promising approach for conditions like metabolic syndrome and MASLD due to its anti-inflammatory potential, its reducing effect on oxidative stress, and its properties that enhance insulin sensitivity. Furthermore, thanks to its high fiber content, it contributes to balancing the gut microbiota and supports the production of short-chain fatty acids (SCFAs), which in turn have positive effects on liver and metabolic health.\n\nEvaluated in terms of fat intake, the DASH diet's emphasis on foods rich in n-3 fatty acids (such as fish and walnuts) provides an anti-inflammatory effect, while limiting saturated and trans fats offers an important strategy for reducing hepatic fat accumulation. Additionally, restricting the consumption of added sugars and fructose may be effective in preventing hepatic steatosis by suppressing lipogenesis processes.\n\nIn light of all these scientific findings, considering the impact of dietary patterns on the development and progression of MASLD, appropriately structuring the diet is critically important for protecting liver health in children. Accordingly, an anti-inflammatory, antioxidant, and metabolically balanced DASH dietary model is considered an effective and applicable approach in the management of pediatric MASLD.\n\nWithin the scope of this study, the effects of implementing the DASH diet in children with MASLD on clinical and metabolic parameters such as liver enzymes, degree of hepatic steatosis, insulin resistance, lipid profile, and inflammatory markers will be evaluated compared to a control group. Additionally, by examining the relationships between these parameters and quality of life as well as dietary adherence, the potential therapeutic role of the DASH diet in the management of pediatric MASLD will be elucidated.",[64],[173,174,175],"MASLD","Diet modification","DASH Diet","2026-03-16",{"date":178,"type":40},"2026-03-18",{"date":180,"type":22},"2026-04-05",{"date":182,"type":22},"2026-12-30",{"name":184,"class":185},"Antalya Training and Research Hospital","OTHER_GOV",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":48},"100588891","phase-1-evaluation-of-miricorilant-on-liver-fat-in-patients-with-masld-100588891","NCT06947304","Evaluation of Miricorilant on Liver Fat in Patients With MASLD","A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Inclusion Criteria:\n\n* AST \\> 17 U\u002FL for women and AST \\> 20 U\u002FL for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of screening showing one of the following:\n\n  1. NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR\n  2. NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR\n  3. NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3\n* MRI-PDFF with ≥ 8% steatosis; this assessment must be performed within 4 weeks of the Baseline Visit.\n* Presence of at least 1 of the following metabolic syndrome characteristics that increase the risk of MASH:\n\n  a. Diagnosis of type 2 diabetes managed with diet alone or diet and metformin (metformin dose must be stable for at least 1 month prior to screening) OR b. Presence of 3 or more components of metabolic syndrome: i. Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or treatment for elevated blood glucose with metformin ii. Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension iii. Serum TG ≥ 150 mg\u002FdL (1.7 mmol\u002FL) iv. Serum high-density lipoprotein cholesterol (HDL) \\\u003C 40 mg\u002FdL (1 mmol\u002FL) in men and \\\u003C 50 mg\u002FdL (1.3 mmol\u002FL) in women or drug treatment for low HDL v. Having overweight or obesity (body mass index \\[BMI\\] ≥ 25 kg\u002Fm2 \\[BMI\n  * 23 kg\u002Fm2 in Asians\\]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm \\[35.4 in\\]; women ≥ 80 cm \\[31.5 in\\] in Asians).\n\nOther inclusion criteria may apply\n\nExclusion Criteria:\n\n* Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 receptor agonists) within the last 3 months.\n* Participation in any other clinical trial within the last 3 months or 5 half-lives of the treatment, whichever is longer.\n* Women who are pregnant, planning to become pregnant, or lactating.\n* BMI \\\u003C 18 kg\u002Fm² or \\> 45 kg\u002Fm².\n* Significant alcohol consumption exceeding 20 g\u002Fday for women or 30 g\u002Fday for men within 1 year prior to screening.\n* Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids.\n* Known or suspected cirrhosis or signs of hepatic decompensation.\n* Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease.\n* History of myocardial infarction, unstable angina, or stroke within 3 months prior to screening.\n* Uncontrolled hypertension (systolic \\> 160 mm Hg or diastolic \\> 100 mm Hg).\n* Current use of medications prohibited due to potential drug-drug interactions with study treatment.\n* Contraindications to magnetic resonance imaging (MRI).\n\nOther exclusion criteria may apply",{"count":194,"type":22},8,[92],"A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)",[70,68,64,95],[97,70,98,99],"2026-02-09",{"date":201,"type":40},"2026-02-11",{"date":203,"type":40},"2025-08-22",{"date":205,"type":22},"2026-05",{"name":108,"class":80},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":116,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100544898","phase-4-fibrosis-lessens-after-metabolic-surgery-100544898","NCT06374875","Fibrosis Lessens After Metabolic Surgery","A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis","FLAMES","Inclusion Criteria\n\nEntry into the study would require that the patient:\n\n1. Is a candidate for general anesthesia\n2. Is eligible for metabolic surgery (RYGB or SG) based on the ASMBS\u002FIFSO 2022 guidelines\n3. Has insurance coverage for metabolic surgery (the requirements may vary in each country)\n4. Is ≥18 and ≤75 years old at the time of signing the informed consent\n5. Has a BMI ≥35 and ≤70 kg\u002Fm2 at the time of first study visit\n6. FIB-4 ≥ 1.3\n7. At least one of the following 5 criteria suggesting presence of advanced fibrosis:\n\n   * LSM ≥ 12 kPa by VCTE using FibroScan®\n   * LSM ≥ 12 kPa by SWE\n   * LSM ≥ 1.7 m\u002Fs by ARFI\n   * LSM ≥ 3.63 kPa MRE\n   * ELF score ≥ 9.8\n8. Patients with and without T2DM are eligible for the study. Patients with T2DM should have been on a stable dose of anti-diabetic medication (including insulin but not semaglutide or tirzepatide or liraglutide) for at least 3 months prior to entry, with glycated hemoglobin (HbA1c) ≤12%.\n9. Self-reported stable weight in 6 months before the first study visit (no weight loss \\>10% within 6 months prior to the first study visit)\n\n   a. In patients with a historical noninvasive tests or liver biopsy, weight loss of no more than 10% is allowed from 6 months prior to the historical tests until the first study visit\n10. Has the ability and willingness to participate in the study, provide informed consent, and agree to any of the arms involved in the study\n11. Can understand the options and comply with the requirements of each arm, including one liver biopsy performed during the screening period (if no adequate biopsy within 12 months before screening is available) and one liver biopsy after 2-years\n12. Has a negative urine pregnancy test at the first and at the randomization visits for women of childbearing potential.\n13. Women of childbearing age must agree to use reliable method of contraception for 2 years\n\n8.2 Exclusion Criteria\n\nPatients who meet the following criteria will be excluded from the study:\n\n1. Known history of other chronic liver diseases (drug induced, viral hepatitis, autoimmune, and genetic):\n\n   * Hepatitis B as detected by presence of hepatitis B surface antigen (HBsAg)\n   * Hepatitis C as detected by presence of hepatitis C virus (HCV) RNA (in case the screening test for hepatitis C is positive, the confirmative test is decisive)\n   * Autoimmune liver disease as diagnosed by antibodies or compatible liver histology\n   * Primary biliary cirrhosis as defined by the presence of at least 2 criteria (elevated alkaline phosphatase, presence of anti-mitochondrial antibody, and histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts)\n   * Primary sclerosing cholangitis\n   * Wilson's disease as diagnosed by low ceruloplasmin or compatible liver histology\n   * Alpha-1-antitrypsin deficiency as diagnosed by alpha1-antitrypsin level or liver histology\n   * Hemochromatosis as diagnosed by HFE mutations (C282Y, H63D), ferritin and transferrin saturation levels, or presence of 3+ or 4+ stainable iron on liver biopsy\n   * Drug-induced liver disease diagnosed by medical history\n   * Known bile duct obstruction\n   * Suspected or proven liver cancer\n2. Weight change \\>10% within 6 months prior to the first study visit or prior to the historical liver biopsy\n3. Treatment with semaglutide, tirzepatide, or liraglutide (for obesity or for T2DM) \\\u003C90 days before the first study visit.\n\n   • However, patients are allowed to participate if they have been on a low dose (or are on older generation GLP-1 agonists) and have lost less than 10% of their body weight since starting the medication.\n4. Type 1 diabetes or autoimmune diabetes\n5. Known cases of human immunodeficiency virus infection\n6. Prior bariatric and metabolic surgery of any kind\n\n   • Reversed procedures such as gastric band or intragastric balloon that have been removed at least 3 months prior to the first study visit are allowed.\n7. Prior complex foregut surgery including any esophageal and gastric surgeries, anti-reflux procedures, biliary diversion, and complex trauma surgery\n8. Any surgery requiring general anesthesia within 1 month prior to signing the consent\n9. History of solid organ transplant\n10. Severe pulmonary disease defined as FEV1 \\\u003C 50% of predicted value\n11. Significant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)\n12. Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V\n13. Classified as New York Heart Association Class IV\n14. Left ventricular ejection fraction \\\u003C25% at the time of screening\n15. Myocardial infarction, unstable angina, stroke, heart surgery, coronary stent placement in the past 6 months\n16. Chronic renal insufficiency with eGFR below 30 mL\u002Fmin\u002F1.73 m2, or being on dialysis\n17. Presence of large hiatal hernia (\\>7 cm)\n18. Presence of Crohn's disease\n19. Psychiatric disorders including (but not limited to) dementia, active psychosis, severe depression requiring 3 or more medications, history of suicide attempts, active alcohol, or substance abuse within the previous 12 months that in the opinion of the investigators could disqualify the patient from metabolic surgery\n20. Pregnancy, the intention of becoming pregnant, or not using adequate contraceptive measures\n21. Breastfeeding\n22. Diagnosis of malignancy within the preceding 3 years (except squamous cell and basal cell cancer of the skin)\n23. Anemia defined as hemoglobin less than 9 g\u002FdL\n24. On therapeutic dose of anticoagulants such as warfarin or direct oral anticoagulants (DOACs)\n25. Known history of clotting disorders, including pulmonary embolus and deep vein thrombosis\n26. Clinical judgment that life expectancy is less than 3 years\n27. Use of investigational therapy within 3 months prior to signing the consent\n28. History of pancreatic carcinoma\n29. Acute pancreatitis \\\u003C 180 days before screening\n30. History or presence of chronic pancreatitis\n31. Presence of concerning thyroid nodule\n32. Uncontrolled thyroid disease: thyroid stimulating hormone (TSH) \\> 6.0 mIU\u002FL or \\\u003C 0.1 mIU\u002FL before the first study visit\n\n    * Patients receiving treatment for hypothyroidism can be included if their thyroid hormone replacement dose has been stable for at least 3 months.\n    * Patients whose TSH is outside the rang but they have normal levels of thyroid hormones can be included.\n33. A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n34. Evidence or history of ascites or spontaneous bacterial peritonitis that require(d) treatment\n\n    • Trace ascites identified only by an abdominal imaging without other evidence of clinically significant portal hypertension and esophageal varices is not an exclusion criterion.\n35. Evidence or history of hepatic encephalopathy\n36. Evidence or history of variceal bleeding\n37. Evidence or history of portosplenic vein thrombosis\n38. Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to the first study visit.\n\n    • Defined as more than 14 units\u002Fweek for females (\\>1 drink per day) and more than 21 units\u002Fweek for males (\\>2 drinks per day) on average, where one unit of alcohol is equivalent to a 12-oz beer, 4-ounce glass of wine, or 1-ounce shot of hard liquor.\n39. Treatment with medications (for more than 14 consecutive days) with known effect on liver steatosis (e.g., treatment with systemic corticosteroids \\[oral or intravenous\\], methotrexate, tamoxifen, valproic acid, amiodarone, or tetracycline) in the 3 months prior to the first study visit (or historical liver biopsy).\n40. ALT or AST or Alkaline phosphatase \\>200 U\u002FL\n41. Recurrent major hypoglycemia or hypoglycemic unawareness\n42. Inability to safely obtain a liver biopsy\n43. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study\n44. Unable to understand the risks, benefits, and compliance requirements of study\n45. Lack capacity to give informed consent\n46. Plans to move outside the primary location of study (country) within the next 24 months\n47. Known or suspected allergy to semaglutide, tirzepatide, liraglutide, excipients, or related products\n48. Previous participation in this trial and got randomized to one of the study groups but did not proceed.\n49. Hospitalization due to COVID-19 within 2 months prior to screening.\n50. Platelet count \\\u003C80,000\n51. International Normalized Ratio (INR) \\>1.7\n52. Child-Pugh score B or C\n53. MELD score ≥15\n54. Upper endoscopy showing gastroesophageal varices\n55. Upper endoscopy showing more than mild portal hypertensive gastropathy\n56. Liver vascular ultrasound (duplex ultrasonography) showing significant portal hypertension characterized by dilated portal vein (\\>13 mm), biphasic or reverse flow in the portal vein, enlarged paraumbilical veins, splenorenal collaterals, or dilated left and short gastric veins.\n\n    Note: Negative findings on upper endoscopy and liver duplex ultrasound (done within one year of the first study visit for both tests) are necessary to establish eligibility for the FLAMES.\n    * Ruling out clinically significant portal hypertension is particularly important in patients with a liver stiffness ≥20 kPa or with a platelet count \\\u003C150,000 per μL or with a (historical) liver biopsy showing cirrhosis.\n    * A subset of patients without having upper endoscopy and liver duplex ultrasound can be eligible for enrollment if their:\n\n      * liver stiffness (by transient elastography using FibroScan®) is between 12 and 15 kPa and their platelet count is \\>150,000 per μL, or\n      * a (historical) liver biopsy showing absence of cirrhosis, or\n      * a (historical) HVPG \\\u003C 5 mmHg\n57. Cross-sectional abdominal imaging (if available historically) indicating presence of large portosystemic collaterals or ascites\n\n    • Splenomegaly alone (in the absence of other radiological and laboratory findings) is not considered to be a sign of clinically significant portal hypertension and is not an exclusion criterion.\n58. HVPG ≥ 12 mmHg (if available historically or if measured at the time of de novo liver biopsy)\n59. Liver biopsy characteristics:\n\n    * F0 in de novo biopsy; Enrollment cap of 20% for F1 in de novo biopsy.\n    * F0 and F1 in historical liver biopsy\n    * Absence of all three components of MASH (steatosis, hepatocyte ballooning, and lobular inflammation) in patients with F1, F2, and F3\n    * Absence of steatosis (\\\u003C5%) in patients with F4\n    * Diagnosis other than MASH",{"count":216,"type":22},120,[218],"PHASE4","Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma. Patients with MASH are also at risk for cardiovascular disease and mortality. There is no universally approved medication for MASH. Weight loss remains the cornerstone of MASH treatment.\n\nPatients meeting the inclusion and exclusion criteria and who give informed consent will be enrolled in the trial and undergo the baseline liver biopsy (if none available). Approximately 120 patients with MASH and liver fibrosis (F1-F4 in baseline liver biopsy) will be randomized in a 1:1 ratio to metabolic surgery or medical treatment (incretin-based therapies ± other medical therapies for MASH) and followed for 2 years at which time a repeat liver biopsy will be performed for the assessment of the primary end point.",[28,221,68,222,223],"Non-Alcoholic Fatty Liver Disease","Liver Fibrosis","Obesity","2025-08-18",{"date":203,"type":40},{"date":227,"type":40},"2024-07-11",{"date":229,"type":22},"2029-12-31",{"name":231,"class":47},"Ali Aminian",22,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":241,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":244,"conditions":245,"keywords":251,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100599634","a-study-to-predict-recompensation-in-patients-with-decompensated-cirrhosis-using-spleen-stiffness-and-simple-blood-tests-100599634","NCT07087041","A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests","Prediction of Recompensation and Stable Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness Combined With Non-Invasive Markers: A Prospective, Observational, Multicenter Study","LEAD-2","Inclusion Criteria:\n\n* Male or female, aged 18 to 75 years (inclusive)\n* Clinically diagnosed decompensated cirrhosis\n* First decompensated event occurred within 12 months of screening, or no decompensated events in the past 12 months despite a history of decompensation\n* Received effective etiological treatment per guidelines:\n\n  * For HBV: Sustained antiviral suppression\n  * For alcohol-related liver disease: Sustained abstinence for ≥2 months\n  * For MAFLD-related cirrhosis: Improved liver function after lifestyle\u002F metabolic intervention\n\nExclusion Criteria:\n\n* Missing data on first decompensated event\n* Prior orthotopic liver transplantation or TIPS\n* Prior splenectomy, splenic embolization, or other shunt surgery\n* History or current diagnosis of hepatocellular carcinoma\n* Acute variceal bleeding within the last 4 weeks or unstable condition\n* Uncontrolled moderate-to-severe ascites\n* Cholestatic cirrhosis; untreated chronic liver diseases; non-cirrhotic portal hypertension; vascular liver diseases (e.g., Budd-Chiari syndrome)\n* Acute or chronic portal vein thrombosis\n* Severe comorbidities of heart, lung, kidney, brain, hematologic, or psychiatric systems\n* Other systemic malignancies (except cured cases)\n* Pregnant or breastfeeding women",{"count":242,"type":22},735,"OBSERVATIONAL","The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of their liver disease. The main questions it aims to answer are:\n\n* Can spleen stiffness and blood test results predict who will get better and stay better after cirrhosis becomes worse?\n* What are the features of people who recover after decompensation?\n\nParticipants will:\n\n* Be people with decompensated cirrhosis who are already getting effective treatment (such as antiviral therapy or alcohol abstinence)\n* Be followed over time to check if they remain stable or have more liver problems\n* Have non-invasive tests done, including spleen stiffness measurement and blood tests\n\nResearchers will track how many participants recover and stay recovered over time, and use that information to build a tool to help predict outcomes in others with cirrhosis.",[246,247,64,248,249,250],"Decompensated Cirrhosis","Hepatitis B Virus (HBV) Infection","Alcohol-Related Liver Disease","Portal Hypertension","Recompensation",[250,246,252],"Spleen Stiffness","2025-07-23",{"date":255,"type":40},"2025-07-25",{"date":257,"type":22},"2025-07-15",{"date":259,"type":22},"2028-12-30",{"name":261,"class":47},"Beijing Friendship Hospital",28]